Literature DB >> 23541879

[The Spanish AIDS Study Group and Spanish National AIDS Plan (GESIDA/Secretaría del Plan Nacional sobre el Sida) recommendations for the treatment of tuberculosis in HIV-infected individuals (Updated January 2013)].

Antonio Rivero1, Federico Pulido, Joan Caylá, José A Iribarren, José M Miró, Santiago Moreno, Inés Pérez-Camacho.   

Abstract

This consensus document was prepared by an expert panel of the Grupo de Estudio de Sida (GESIDA [Spanish AIDS Study Group]) and the Plan Nacional sobre el Sida (PNS [Spanish National AIDS Plan]). The document updates current guidelines on the treatment of tuberculosis (TB) in HIV-infected individuals contained in the guidelines on the treatment of opportunistic infections published by GESIDA and PNS in 2008. The document aims to facilitate the management and treatment of HIV-infected patients with TB in Spain, and includes specific sections and recommendations on the treatment of drug-sensitive TB, multidrug-resistant TB, and extensively drug-resistant TB, in this population. The consensus guidelines also make recommendations on the treatment of HIV-infected patients with TB in special situations, such as chronic liver disease, pregnancy, kidney failure, and transplantation. Recommendations are made on the timing and initial regimens of antiretroviral therapy in patients with TB, and on immune reconstitution syndrome in HIV-infected patients with TB who are receiving antiretroviral therapy. The document does not cover the diagnosis of TB, diagnosis/treatment of latent TB, or treatment of TB in children. The quality of the evidence was evaluated and the recommendations graded using the approach of the Grading of Recommendations Assessment, Development and Evaluation Working Group.
Copyright © 2013 Elsevier España, S.L. All rights reserved.

Entities:  

Keywords:  Anti-retroviral treatment; Antituberculous therapy; Extensively drug-resistant tuberculosis; Fármacos antituberculosos; Human immunodeficiency virus; Multidrug-resistant tuberculosis; Tratamiento antirretroviral; Tuberculosis; Tuberculosis con resistencia extendida; Tuberculosis multirresistente; Virus de la inmunodeficiencia humana

Mesh:

Substances:

Year:  2013        PMID: 23541879     DOI: 10.1016/j.eimc.2013.02.001

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  2 in total

1.  A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.

Authors:  Gregory D Huhn; Pablo Tebas; Joel Gallant; Timothy Wilkin; Andrew Cheng; Mingjin Yan; Lijie Zhong; Christian Callebaut; Joseph M Custodio; Marshall W Fordyce; Moupali Das; Scott McCallister
Journal:  J Acquir Immune Defic Syndr       Date:  2017-02-01       Impact factor: 3.731

2.  Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Authors:  Frank A Post; Pablo Tebas; Amanda Clarke; Laurent Cotte; William R Short; Michael E Abram; Shuping Jiang; Andrew Cheng; Moupali Das; Marshall W Fordyce
Journal:  J Acquir Immune Defic Syndr       Date:  2017-02-01       Impact factor: 3.731

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.